1 2 Whole exome sequencing (WES) is increasingly utilized in both clinical and non-clinical 3 settings, but little is known about the utility of WES in healthy individuals. In order to 4 determine the frequency of both medically actionable and non-actionable but medically 5 relevant exome findings in the general population we assessed the exomes of 70 participants 6 who have been extensively characterized over the past several years as part of a longitudinal 7 integrated multi-omics profiling study at Stanford University. We assessed exomes for rare 8 likely pathogenic and pathogenic variants in genes associated with Mendelian disease in the 9
Introduction

25
Whole genome sequencing (WGS) and exome sequencing (WES) play increasingly important 26 roles in providing molecular diagnoses for Mendelian disease (Manolio et al. 2013) , as well 27 as identifying potential driver mutations in patients with cancer. However, our understanding 1 In this research study we examine the utility of WES for the general population by using 2 established guidelines to perform an in-depth search for variants with potential medical 3 significance in a group of 70 unrelated adult volunteers enrolled in a longitudinal wellness 4 study. Our analysis included variants in all genes previously associated with Mendelian 5 genetic diseases in the Online Mendelian Inheritance in Man (OMIM) database 6 (http://www.omim.org) or on the list of 59 ACMG genes. In addition, we assessed 1 
5
The gene coding regions were sequenced using an enhanced exome sequencing strategy that (Table 3) and include five variants classified as pathogenic with strong evidence 23 suggestive of a causative role in disease as per ACMG classification guidelines; five 24 classified as likely pathogenic; and one variant that was identified in two individuals was moderate risk allele for colon cancer, and has issued screening guidelines for heterozygous 1 carriers of this mutation (Boursi et al. 2013; Liang et al. 2013 ; National Comprehensive 2 Cancer Network 2016). In total, 12 of the 70 individuals in the cohort (17%) had medically 3 actionable likely pathogenic or pathogenic variants identified (see Table 3 for the complete 4 list of actionable variants). Of the 12 variants, six reside in the 59 genes reported as actionable 5 in the most recent ACMG guidelines regarding incidental findings (Green et al. 2013 
10
The remaining six variants reside in genes that are not included in the ACMG guidelines but 11 that are associated with medically actionable disease as defined in the methods. (Green et al. 2013 ).
2
Heterozygotes for MUTYH mutations are, however, at increased risk for developing colon cancer, and the National 3 Comprehensive Cancer Network (NCCN) recommends increased screening for mutation carriers (Win et al. 2014;  4 National Comprehensive Cancer Network 2016).
c
This APC mutation does not cause traditional familial adenomatous polyposis, but rather, has been shown to 6 increase risk for colon cancer, and the NCCN recommends increased surveillance for carriers of this specific 7 mutation (Boursi et al. 2013; Liang et al. 2013 ; National Comprehensive Cancer Network 2016).
8
d This evidence was used as "moderate" level evidence as per ACMG guidelines.
9
(2) indicates that two participants were heterozygous for this mutation.
10
All variants in 3 mutations is considerably more responsive to sulphonylurea drugs. Early recognition of 4 HNF1A-MODY and subsequent initiation of sulphonylurea therapy may reduce the incidence 5 of diabetic complications (Shepherd et al. 2009; Bacon et al. 2016 ). The participant, who was 6 currently managing her diabetes with a combination of three non-sulphonylurea oral 7 medications, was referred to endocrinology to discuss potential changes to her treatment plan, 8 and her three children also underwent genetic testing for the mutation to inform diabetes 9 screening regimens. 
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Among the criticisms of the ACMG list is the lack of agreement among experts on the 22 ACMG panel that compiled the list over which findings should be reported, as well as the 23 existence of numerous other genes in which mutations can cause highly penetrant and 24 treatable or preventable disease (Burke et al. 2013; Holtzman 2013) . Our findings, which 25 include several medically actionable pathogenic or likely pathogenic variants in genes not 26 included in the latest version of the ACMG list, support this concern. In addition to mutations 27 in genes on the ACMG list we identified pathogenic or likely pathogenic variants in six other genes not on the ACMG list that have medical relevance, including two (HNF1A and RBM20) 1 in which participants had personal and/or family medical history consistent with 2 pathogenicity.
4
In addition to HNF1A and RBM20 mutations, we identified mutations in other noteworthy 5 genes. As previously noted, one participant was found to carry a likely pathogenic MUTYH 6 mutation. Current ACMG guidelines for the reporting of incidental findings recommend only 7 reporting compound heterozygote or homozygous mutations in MUTYH, as MUTYH-8 associated polyposis is considered a recessive disease (Green et al. 2013; Kalia et al. 2017 Parkinson's disease. Qualitative research on this subject has suggested many individuals find 9 this information actionable in other (non-medical) ways and express that they would live their 10 lives differently if they knew they were at increased risk of developing such a condition or 11 would prepare for developing the disease (Clift et al. 2015; Yushak et al. 2016 ). Our study 12 identified 21 participants with one or two copies of the APOE e4 allele, which significantly 13 increases lifetime risk for developing Alzheimer's disease (Corder et al. 1993 Our study had several limitations. Among them, we used a minor allele frequency cutoff of 20 0.5% when filtering variants for further curation, and this will certainly lead to the exclusion 21 of some particularly common pathogenic and likely pathogenic variants, such as the common delta 508 CFTR mutation. Other filtering cutoffs also likely limited the number of disease-23 causing mutations identified. Our cohort size (70) is small and larger studies will be needed to 24 determine if the rate of actionable findings identified in our cohort also applies to larger 25 populations. Our understanding of penetrance in many disease genes is based largely on 26 studies of families known to be affected with disease, so in the future we may learn that 27 penetrance is lower for individuals without family histories of disease who have actionable mutations described in this study. 
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Participants had varying degrees of personal and family medical history available for the 16 curators to take into consideration when classifying variants. For some participants this 17 information was limited to a medical history intake form and basic medical records; for others 18 much more extensive medical history and/or a three-generation pedigree were available.
19
Additional variants were curated when they were identified in genes associated with a 20 potentially Mendelian disease in the participant's family history.
21
Participants in whom medically significant likely pathogenic or pathogenic variants were 23 identified were encouraged to discuss the results with their physician and, when necessary, 24 referred to a genetics clinic for follow up. Participants were given the option at the time of 25 consent of selecting whether they would like to receive genomic results, and if so, whether 26 they would prefer actionable results only or all medically relevant results identified.
associated with diseases that are moderately to highly penetrant, the identification of which 1 was likely to result in altered medical care in the form of treatment, screening, or preventative 2 measures. Additionally, non-actionable findings with medical relevance were returned to 3 participants who opted to receive them during the consent process. These results included 4 likely pathogenic and pathogenic heterozygous variants in genes implicated in recessive 5 diseases, as well as likely pathogenic and pathogenic variants in genes associated with 6 diseases such as Parkinson's disease or Alzheimer's disease, for which limited or no highly 7 effective treatment or preventative measures are available. All pathogenic and likely 8 pathogenic variants were reviewed by two genetic counselors and a medical geneticist.
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Results were then reported back to participants by a genetic counselor in accordance with 10 their stated preferences.
12
Participants' genotypes were also examined for common SNPs with pharmacogenetic 13 annotations that reached a level 1A classification in the PharmGKB database (pharmgkb.org). 
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